

# Viktor Dahl

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2356874/publications.pdf>

Version: 2024-02-01

19  
papers

2,098  
citations

623734

14  
h-index

794594

19  
g-index

20  
all docs

20  
docs citations

20  
times ranked

2855  
citing authors

#	ARTICLE	IF	CITATIONS
1	Transmission of viral hepatitis through blood transfusion in Sweden, 1968 to 2012. <i>Eurosurveillance</i> , 2020, 25, .	7.0	6
2	Lyme neuroborreliosis epidemiology in Sweden 2010 to 2014: clinical microbiology laboratories are a better data source than the hospital discharge diagnosis register. <i>Eurosurveillance</i> , 2019, 24, .	7.0	15
3	A nationwide outbreak of listeriosis associated with cold-cuts, Sweden 2013-2014. <i>Infection Ecology and Epidemiology</i> , 2017, 7, 1324232.	0.8	10
4	Self-reported infections during international travel and notifiable infections among returning international travellers, Sweden, 2009-2013. <i>PLoS ONE</i> , 2017, 12, e0181625.	2.5	13
5	Communicable Diseases Prioritized According to Their Public Health Relevance, Sweden, 2013. <i>PLoS ONE</i> , 2015, 10, e0136353.	2.5	14
6	Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation. <i>Aids</i> , 2014, 28, 2251-2258.	2.2	125
7	An Example of Genetically Distinct HIV Type 1 Variants in Cerebrospinal Fluid and Plasma During Suppressive Therapy. <i>Journal of Infectious Diseases</i> , 2014, 209, 1618-1622.	4.0	47
8	Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies. <i>PLoS Pathogens</i> , 2013, 9, e1003174.	4.7	524
9	The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. <i>Blood</i> , 2013, 121, 4635-4646.	1.4	117
10	Single-copy assay quantification of HIV-1 RNA in paired cerebrospinal fluid and plasma samples from elite controllers. <i>Aids</i> , 2013, 27, 1145-1149.	2.2	19
11	Treatment Intensification with Raltegravir in Subjects with Sustained HIV-1 Viraemia Suppression: A Randomized 48-Week Study. <i>Antiviral Therapy</i> , 2012, 17, 355-364.	1.0	108
12	A Randomized, Controlled Trial of Raltegravir Intensification in Antiretroviral-treated, HIV-infected Patients with a Suboptimal CD4+ T Cell Response. <i>Journal of Infectious Diseases</i> , 2011, 203, 960-968.	4.0	176
13	Raltegravir Treatment Intensification Does Not Alter Cerebrospinal Fluid HIV-1 Infection or Immunoactivation in Subjects on Suppressive Therapy. <i>Journal of Infectious Diseases</i> , 2011, 204, 1936-1945.	4.0	67
14	Intensification of Antiretroviral Therapy with a CCR5 Antagonist in Patients with Chronic HIV-1 Infection: Effect on T Cells Latently Infected. <i>PLoS ONE</i> , 2011, 6, e27864.	2.5	84
15	Can HIV infection be eradicated through use of potent antiviral agents?. <i>Current Opinion in Infectious Diseases</i> , 2010, 23, 628-632.	3.1	17
16	HIV reservoirs, latency, and reactivation: Prospects for eradication. <i>Antiviral Research</i> , 2010, 85, 286-294.	4.1	100
17	HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. <i>Nature Medicine</i> , 2010, 16, 460-465.	30.7	500
18	Establishment of Drug-Resistant HIV-1 in Latent Reservoirs. <i>Journal of Infectious Diseases</i> , 2009, 199, 1258-1260.	4.0	14

#	ARTICLE	IF	CITATIONS
19	<i>Chlamydia trachomatis</i> infection and persistence of human papillomavirus. International Journal of Cancer, 2005, 116, 110-115.	5.1	141